- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Lupin Limited — Important, 20-08-2026: Arrangements for strategic, technical, manufacturing, or marketing tie up
20-08-2026 | 10:46 am
20-08-2026 | 10:46 am
Lupin's subsidiary VISUfarma inked an exclusive deal with Visus Therapeutics to commercialize YUVEZZI™ for presbyopia in Europe. This strengthens Lupin’s ophthalmology portfolio and expands its specialty business, targeting long-term growth. The deal involves up to €7.5 Cr plus royalties.
No comments yet. Be the first to comment!